Sign In
Buy GLP
$48.45
-0.81 (-1.64%)
At Close: Jun 03, 2026
New findings demonstrated that a single dose of Rejuva was well tolerated in healthy animals, with no evidence of toxicity
China's Sciwind's GLP-1 shows similar weight loss to Novo's Wegovy, study finds
03:52pm, Saturday, 21'st Jun 2025
Overweight patients given an experimental weight loss drug being developed by China's Sciwind Biosciences lost an average of 10% to 15% of their body weight, roughly in line with results from a simila
Novo Nordisk: Ignored GLP-1 Leader Is Now A Deep Value Play
09:30am, Saturday, 21'st Jun 2025
NVO's bottom has finally materialized after the painful halving from June 2024 peaks, as the GLP-1 compounding/supply headwinds moderate. This is significantly aided by the expanded partnership with n
The investigational once-daily pill lowered A1C by an average of 1.3% to 1.6% across doses, with improvements seen as early as four weeks, in adults with type 2 diabetes In ACHIEVE-1, orforglipron
Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutide
11:29am, Wednesday, 18'th Jun 2025
Company announcement – No. 15 / 2025 Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutide Body weight reductions of a mean
Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside.
09:53am, Wednesday, 18'th Jun 2025
Eli Lilly (LLY -0.41%) has been one of the hottest healthcare stocks to own in recent years, thanks in large part to the success of its incredibly successful GLP-1 agonist drugs, which help patients w
Dose-dependent, marked reductions in food intake and significant weight loss observed in obese cynomolgus monkeys BMF-650 compared favorably to published data of a leading GLP-1 RA candidate IND filin
Omada Health's Enhanced GLP-1 Care Track Demonstrates Increased Medication Persistence and Weight Loss Outcomes at 12 and 24 Weeks
09:00am, Tuesday, 17'th Jun 2025
SAN FRANCISCO, June 17, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, released new data1 demonstrating that Omada's GLP-1 companion program signi
WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (“Global”) announced today that the cash tender offer (the “Offer”) commenced on June 10, 2025 to purchase any and all of the ou
Global Partners (GLP), a Top Stock to Buy Amid the Spike in Oil Prices
06:16pm, Monday, 16'th Jun 2025
Operating one of the largest terminal networks of refined petroleum products in the Northeastern United States, Global Partners (GLP) is an appealing stock to consider amid the sharp spike in crude oi
Global Partners LP Announces Pricing Terms of Cash Tender Offer for Any and All Outstanding 7.00% Senior Notes Due 2027
04:05pm, Monday, 16'th Jun 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (“Global”) announced today the pricing terms of the previously announced cash tender offer (the “offer”) to purchase any and all
Modular Medical to Present Data from Study Examining Pump Delivery of a GLP-1R Agonist at the ADA 85th Scientific Sessions
08:00am, Monday, 16'th Jun 2025
SAN DIEGO, CA / ACCESS Newswire / June 16, 2025 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump
iBio nominates IBIO-610 as development candidate for its first-in-class Activin E antibody New study aims to evaluate the half-life of IBIO-610 in obese, elderly non-human primates (NHP) and assess ea
The 9.2% Yield Of The Preferred Stock Of Global Partners Is Highly Attractive
10:57pm, Sunday, 15'th Jun 2025
Global Partners' preferred stock offers a 9.2% yield with strong dividend safety, appealing to income-focused and conservative investors amid market volatility. The company demonstrates resilience to
BURLINGTON, Mass., June 13, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company), a metabolic therapeutics company focused on pattern-breaking approaches to treat the root causes
